Fabhalta (iptacopan) Patient Assistance Program
Don’t let the high cost of brand oral factor B inhibitor disrupt your paroxysmal nocturnal hemoglobinuria treatment. We help eligible patients access Fabhalta (iptacopan capsules) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Fabhalta (iptacopan) is FDA-approved for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults, and for IgA nephropathy in adults at risk of rapid disease progression. First-in-class oral factor B inhibitor — blocks the alternative complement pathway. The first oral PNH therapy — a dramatic advance in convenience vs IV/SC options.
- Without assistance, Fabhalta costs commonly run approximately $28,000+ per month.
- Through AffordMyPrescriptions, qualifying patients can access Fabhalta for a flat $69.95 per month.
- Other PNH therapies (all IV or SC): Soliris (eculizumab — IV every 2 weeks; original C5 inhibitor), Ultomiris (ravulizumab — long-acting IV every 8 weeks or SC), Piasky (crovalimab — SC every 4 weeks), Empaveli (pegcetacoplan — SC twice weekly; C3 inhibitor). Fabhalta is uniquely oral. All complement inhibitors carry meningococcal infection risk — vaccination essential. IgA nephropathy therapy: RAAS blockade (generic), Kerendia (finerenone), Filspari (sparsentan), corticosteroids, and others.
What is Fabhalta Prescription Assistance Program?
The Fabhalta Patient Assistance Program helps eligible patients access this oral factor B inhibitor at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Fabhalta PAP enrollment for a flat $69.95 per month — so you never face a gap in Fabhalta PNH or IgA nephropathy therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Fabhalta enrollment — so you never face a gap in your PNH or IgA nephropathy treatment.
Pharmacy Price Comparison
- Without assistance, Fabhalta costs tens of thousands per month. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Piasky (SC C5 alt) | ~$32,000/mo | Alt SC C5 inhibitor |
| Specialty pharmacy | ~$28,000/mo | Save substantially |
| Walgreens Specialty | ~$29,000/mo | Save substantially |
| CVS Specialty | ~$30,000/mo | Save substantially |
| 340B-eligible institution | ~$24,000/mo | Save substantially |
| Soliris (IV C5 alt) | ~$35,000/mo | Alt C5 inhibitor IV |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Fabhalta — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Fabhalta Prescription Program?
The Fabhalta Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. The first oral PNH therapy transforms treatment convenience. Meningococcal vaccination is essential for all complement inhibitors. PNH is an ultra-rare disease requiring hematology specialty care.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Fabhalta assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Fabhalta is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Fabhalta:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $28,000+ per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Fabhalta assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Fabhalta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Fabhalta:
Fabhalta is the first-in-class oral factor B inhibitor and the first oral therapy for paroxysmal nocturnal hemoglobinuria (PNH) — blocking the alternative complement pathway upstream of C5. It is also approved for IgA nephropathy at risk of rapid progression. A novel oral option in the complement-mediated disease landscape.
How It Works:
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by intravascular hemolysis and thrombosis. Missing GPI-anchored complement regulatory proteins (CD55, CD59) render PNH red cells vulnerable to complement-mediated destruction. IgA nephropathy involves alternative complement pathway activation in glomeruli. Both diseases involve complement dysregulation. Iptacopan is an oral factor B inhibitor — factor B is a key component of the alternative complement pathway convertase. It blocks the alternative complement pathway upstream of C5. In PNH, it prevents both intravascular hemolysis (like C5 inhibitors) AND extravascular hemolysis (unlike C5 inhibitors) — potentially improving hemoglobin response. In IgA nephropathy, it reduces alternative complement activation. A first-in-class oral therapy — a dramatic convenience advantage.
Form and Use:
Fabhalta capsules. Twice-daily oral dosing. Requires meningococcal vaccination completed at least 2 weeks before starting (or antibiotic prophylaxis if urgent). Also consider H. influenzae type b and pneumococcal vaccination given complement inhibition. Hematology specialty prescribing.
Generic Availability:
No generic Fabhalta. Other PNH therapies: Soliris (eculizumab — original C5 inhibitor, IV every 2 weeks after loading; biosimilars emerging), Ultomiris (ravulizumab — long-acting C5 inhibitor, IV every 8 weeks or SC), Piasky (crovalimab — SC every 4 weeks; novel C5 inhibitor), Empaveli (pegcetacoplan — C3 inhibitor, SC twice weekly). Fabhalta is uniquely oral. IgA nephropathy therapy: RAAS blockade (ACE inhibitors, ARBs — generic; foundation), Kerendia (finerenone), Filspari (sparsentan — for IgA nephropathy), corticosteroids, and others. Aplastic Anemia and MDS International Foundation and IgA Nephropathy Foundation resources.
Warnings:
Meningococcal infection (BOXED WARNING — complement inhibition impairs immune defense against encapsulated bacteria; meningococcal vaccination essential at least 2 weeks before starting, or antibiotic prophylaxis if urgent; educate patients on infection symptoms — fever, headache, rash, mental status changes; immediate ED evaluation for any infection symptoms), other encapsulated bacterial infections (pneumococcal, H. influenzae b — vaccinate), hyperlipidemia (monitor), embryo-fetal considerations, hepatotoxicity (monitor LFTs), drug interactions (CYP2C8 substrate). Other: headache, upper respiratory infections, nasopharyngitis. Hematology specialty care essential. Ongoing infection vigilance is critical.
FAQ (Frequently Asked Questions)
How much does Fabhalta cost without insurance?
$28,000+ per month at specialty pharmacies. Similar to other complement inhibitors ($28,000–$35,000/month). Patient Assistance Programs are essential.
How is Fabhalta different from Soliris, Ultomiris, and Piasky?
Fabhalta (iptacopan) is an oral factor B inhibitor — blocking the alternative complement pathway upstream of C5. Soliris, Ultomiris, and Piasky are IV or SC C5 inhibitors — blocking terminal complement at C5. Fabhalta is oral (a dramatic convenience advantage) and may improve hemoglobin response vs C5 inhibitors. C5 inhibitors have longer clinical experience.
How is Fabhalta different from Empaveli?
Both act upstream of C5. Empaveli (pegcetacoplan) is a C3 inhibitor — SC twice weekly. Fabhalta is a factor B inhibitor — oral twice daily. Different targets in the alternative complement pathway and different administration. Both may improve hemoglobin response vs C5 inhibitors.
Why do I need meningococcal vaccination before Fabhalta?
Complement inhibition impairs immune defense against encapsulated bacteria — particularly Neisseria meningitidis. Meningococcal infection can be rapidly fatal. Vaccination is required at least 2 weeks before starting (or antibiotic prophylaxis if urgent). Educate patients on infection symptoms — seek immediate evaluation for any concerns.
What is Fabhalta's role in IgA nephropathy?
It is also FDA-approved for IgA nephropathy at risk of rapid progression — reducing alternative complement activation implicated in IgA nephropathy pathogenesis. Combined with RAAS blockade (foundation therapy). A newer therapy for IgA nephropathy — nephrology specialty care.
Take Control of Your Medication Costs
The first oral PNH therapy revolutionizes treatment convenience. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.